Table 1.
Patient Characteristics.
| Number of patients | 57 (100%) | |
| Gender, n | female | 56 (98%) |
| male | 1 (2%) | |
| Age, years | 60.0 (28-84) | |
| Height, m | 1.56 (1.45-1.70) | |
| Body weight, kg | 53.9 (40.3-100) | |
| BMI, kg/m2 | 21.8 (17.2-40.2) | |
| Histories, n | allergy | 26 (46%) |
| smoking | 19 (33%) | |
| alcohol consumption | 24 (42%) | |
| Treatment settings, n | pre-operative | 20 (35%) |
| post-operative | 10 (18%) | |
| recurrent | 15 (26%) | |
| stage IV | 12 (21%) | |
| Drugs combined with Pmab-Tmab, n | docetaxel | 39 (68%) |
| paclitaxel | 5 (9%) | |
| capecitabine | 1 (2%) | |
| exemestane | 1 (2%) | |
| none | 11 (19%) | |
| Previous history of chemotherapy, n | ||
| any time | 45 (79%) | |
| within 3 months | Total | 38 (67%) |
| anthracycline + cyclophosphamide | 30 (53%) | |
| paclitaxel | 1 (2%) | |
| Tmab | 4 (7%) | |
| Tmab + paclitaxel | 1 (2%) | |
| lapatinib + capecitabine | 1 (2%) | |
| capecitabine | 1 (2%) | |
| none | 12 (21%) | |
| Estrogen receptor, n | positive | 36 (63%) |
| negative | 21 (37%) | |
| IR occurrence, n | yes | 25 (44%) |
| no | 32 (56%) |
Data are median value (range) or n (%).
BMI, body mass index; Pmab, Pertuzumab; Tmab, Trastuzumab